Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies demonstrated that the proinflammatory cytokine interleukin (IL)-32 is implicated in the pathogenesis of other inflammatory diseases. Objectives To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD). Methods Tissue samples were obtained from healthy skin and lesional HS, psoriatic and AD skin to analyse the expression of IL-32 by immunohistochemistry and semiquantitative real-time polymerase chain reaction. The cellular source of the cytokine was determined by double immunofluorescence staining. Serum from the four donor groups was used to measure systemic levels of IL-32 by enzymelinked immunosorbent assay. Results IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis. In HS, IL-32 was found to be expressed by natural killer cells, T cells, macrophages and dendritic cells in highly infiltrated areas of the dermis. High IL32 mRNA levels in lesional HS skin coincided with high amounts of T cells and macrophages. Additionally, IL32 mRNA levels in lesional HS skin correlate positively with interferon-c and IL-17A and negatively with IL-13. Conclusions Our findings suggest that IL-32 is overexpressed in HS. Targeting IL-32 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease.
Summary
Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies demonstrated that the proinflammatory cytokine interleukin (IL)-32 is implicated in the pathogenesis of other inflammatory diseases. Objectives To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD). Methods Tissue samples were obtained from healthy skin and lesional HS, psoriatic and AD skin to analyse the expression of IL-32 by immunohistochemistry and semiquantitative real-time polymerase chain reaction. The cellular source of the cytokine was determined by double immunofluorescence staining. Serum from the four donor groups was used to measure systemic levels of IL-32 by enzymelinked immunosorbent assay. Results IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis. In HS, IL-32 was found to be expressed by natural killer cells, T cells, macrophages and dendritic cells in highly infiltrated areas of the dermis. High IL32 mRNA levels in lesional HS skin coincided with high amounts of T cells and macrophages. Additionally, IL32 mRNA levels in lesional HS skin correlate positively with interferon-c and IL-17A and negatively with IL-13. Conclusions Our findings suggest that IL-32 is overexpressed in HS. Targeting IL-32 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease.
What's already known about this topic?
• The immune system is dysregulated in lesions of hidradenitis suppurativa (HS).
• Interleukin (IL)-32 is a proinflammatory cytokine upregulated in various inflammatory diseases.
What does this study add?
• The proinflammatory cytokine IL-32 is upregulated in lesional HS skin and is also elevated systemically.
• IL-32 levels positively correlate with interferon-c and IL-17 levels in lesional HS skin.
• No upregulation of IL-32 was detected in psoriasis and atopic dermatitis, two other inflammatory skin diseases.
What is the translational message?
• This study suggests that IL-32 is involved in the pathogenesis of HS and is thus a potential therapeutic target.
Hidradenitis suppurativa (HS), also termed 'acne inversa', is an inflammatory disease of the skin. In its early stages, HS manifests through painful subcutaneous nodules in the axillary, inguinal and anogenital regions of the body. Becoming chronic or recurrent, the lesions progress into deep dermal abscesses with draining sinuses and fistulae, accompanied by malodorous suppuration. 1 HS is painful and lowers the quality of life of affected patients to a higher degree than other inflammatory skin diseases. 2 Therapy of this recalcitrant disease is highly challenging. One of the main reasons for the lack of efficient therapies is the poor understanding of HS pathogenesis. Nowadays, the trigger for HS is believed to be follicular keratinization, inducing occlusion, dilation and rupture of the pilosebaceous unit, followed by an infiltration of inflammatory cells into the dermis with subsequent dysregulation of the immune system. 3, 4 Interleukin (IL)-32 is a proinflammatory cytokine that is expressed by several immune cells. 5 It comprises eight exons, and seven alternatively spliced isoforms have been proposed. [6] [7] [8] The four main isoforms are IL-32a, IL-32b, IL-32c
and IL-32d, with IL-32a being the most abundant and IL-32c the most biologically active. 6, 9 Several proinflammatory mediators initiate IL-32 production, including interferon (IFN)-c, IL-1b, IL-12 and IL-18. 6 In turn, IL-32 increases the production of the cytokines tumour necrosis factor (TNF)-a, IL-1b and IL-6, 6,9 and also of the chemokines IL-8, CCL2, CCL4 and CCL5. 6, 10, 11 Moreover, IL-32 was shown to upregulate the adhesion molecules ICAM-1 and sVCAM-1 10, 12 and the antimicrobial peptide (AMP) cathelicidin. 13 In addition to its proinflammatory features, IL-32 negatively impacts on cancer cell growth 14 and has a protective role in viral and bacterial infections. [15] [16] [17] In this study, we investigated the expression of IL-32 in HS and examined how HS inflammation differs from that of other inflammatory skin diseases. Numerous mediators that are involved in the induction and function of IL-32 are known to be upregulated in HS, namely IFN-c, IL-1b, IL-6, IL-12, IL-18, TNF-a, cathelicidin and CCL5. [18] [19] [20] [21] [22] [23] Furthermore, IL-32 is dysregulated in diseases that are associated with HS, such as inflammatory bowel disease and ankylosing spondylitis, [24] [25] [26] [27] making IL-32 a possible linking factor in the pathogenesis of these diseases.
To elucidate the expression of IL-32 in HS lesions, we performed immunohistochemistry and semiquantitative real-time polymerase chain reaction (PCR) and determined the cellular source of IL-32 by double immunofluorescence staining. Additionally, IL32 mRNA levels in HS skin were correlated with lesional inflammatory status and the principal T helper cell (Th)1, Th2 and Th17 cytokines (IFN-c, IL-13 and IL-17). To complete our analysis, we investigated systemic IL-32 levels. In order to show the relevance of IL-32 in HS pathogenesis, we compared expression of IL-32 in patients with HS not only with healthy donors, but also with patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).
Materials and methods

Samples from patients
This study followed the Declaration of Helsinki protocols and was approved by the medical ethics committee of the canton of Berne, Switzerland. Before enrolment, all patients gave written informed consent. Study patients were not previously treated with biologics or systemic immunomodulatory drugs, and systemic antibiotics were stopped at least 8 weeks before skin biopsy or blood donation. Skin biopsies were obtained from 20 patients with HS (12 women and eight men; 50% obese and 92% smokers; median age 37Á5 years, range 21-51). These patients had HS with a mean Hurley stage of 2Á3 AE 0Á66. Furthermore, skin biopsies from eight patients with psoriasis (two women and six men; median age 47Á5 years, range 30-61) and eight patients with AD (five women and three men; median age 20Á5 years, range 18-47) were collected. Biopsies were targeted at the central area of the lesions. Healthy control skin was obtained from 10 donors (six women and four men; median age 41Á5 years, range 23-66).
Tissue samples were immediately embedded in optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA, U.S.A.), snap frozen and stored at À70°C. Serum was obtained from 17 patients with HS (eight women and nine men; 54% obese; 86% smokers; median age 37 years, range 21-55), 11 patients with psoriasis (four women and seven men; median age 54 years, range 29-61), nine patients with AD (five women and four men; median age 32 years, range 20-63) and five healthy donors (two women and three men; median age 24 years, range [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Serum was stored at À20°C.
RNA isolation and complementary DNA synthesis
As previously described, 18 OCT-embedded tissue specimens were cut into 10-lm sections. Next, RNA was extracted by means of the RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA, U.S.A.). Contaminating DNA was removed with an RNase-free DNase step (Qiagen). Complementary DNA was synthesized using the BD Reverse Transcriptase Kit (BD Biosciences, San Diego, CA, U.S.A.).
Semiquantitative real-time polymerase chain reaction analysis
PCR primers and probes were purchased from Applied Biosystems (Foster City, CA, U.S.A.) as premade Taqman gene expression assays. The following primer pairs, spanning exonexon borders, were used: IL-32 (Hs00992441_m1), IL-32a (Hs04353657_gH), IL-32b (Hs04353658_gH), IL-32c (Hs04353656_g1), IL-32d (Hs04353659_gH), IFN-c (Hs00174143_m1), IL-17 (Hs00174383_m1), IL-13 (Hs00174379_m1) and three reference genes: b 2 -microglobulin (Hs99999907_m1), glyceraldehyde-3-phosphate dehydrogenase (Hs99999905_m1) and hypoxanthine phosphoribosyltransferase-1 (Hs99999909_m1). The semiquantitative real-time PCR was performed with an ABI-Prism 7300 Sequence Detector System (Applied Biosystems) as described previously. 18 The results are expressed as fold difference. To determine these differences, relative units were calculated by the 2 ÀDDCt method. The threshold cycle (Ct) for the reference genes was determined using the geometric mean of the Ct of the three reference genes. 28 In samples where no Ct value could be determined, the value was set to 40, as described previously. 29 
Immunohistochemical staining
Immunostaining was performed as described previously. 18 In brief, cryostat-cut tissue sections were air dried, fixed in 4% icecold acetone (10 min) and rehydrated in 0Á1% saponin containing Tris-buffered saline. After blocking (Roti-ImmunoBlock; Roth GmbH, Karlsruhe, Germany) for 15 min, the sections were incubated with the primary antibody for 1 h at room temperature, followed by a 1-h incubation with a biotinylated secondary antibody (Table 1) , and thereafter with the streptavidin-biotin complex/alkaline phosphatase method (BD Biosciences). Finally, sections were developed with Fuchsin Substrate-Chromogen (Dako, Santa Clara, CA, U.S.A.) and counterstained with haematoxylin for 3 min. As a negative control, the same tissue was stained with the secondary antibody only.
To score the inflammatory status of HS biopsies, slides were stained for CD3, CD68 and CD66b (Table 1) . Stained cell density and cell distribution across the biopsy were assessed and included in the allocation of the score as described previously. 30 Briefly, CD3, CD68 and CD66b were assessed using a semiquantitative scale: 0 = absent; 1 = weak/low expression with little distribution; 2 = moderate expression with intermediate distribution; 3 = strong expression with wide distribution. The inflammatory score was calculated by taking the mean of the scores for CD3, CD68 and CD66b.
Immunofluorescence double staining
Colocalization of IL-32 with natural killer cell, T-cell, macrophage and dendritic cell markers (CD56, CD3, CD68, CD11c) was assessed (Table 1) . Double immunofluorescence was performed as described previously. 18 Briefly, after pretreatment (see above), sections were exposed to the primary IL-32 antibody for 1 h, followed by an antirabbit Alexa Fluor 594 conjugate (Invitrogen, Carlsbad, CA, U.S.A.). Sections were then incubated for 1 h with one of the following antibodies (Table 1) : (i) anti-CD56, (ii) anti-CD3, (iii) anti-CD68 or (iv) anti-CD11c, before staining with isotype-specific Alexa
Fluor 488-conjugated goat antimouse antibodies (Invitrogen). DAPI (4ʹ,6-diamidino-2-phenylindole) Fluoromount-G (Southern Biotech, Birmingham, AL, U.S.A.) was used to stain cell nuclei.
Enzyme-linked immunosorbent assay
To detect IL-32 in the serum, the IL-32 DuoSet enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, U.S.A.) was used as per the manufacturer's instructions. The results are expressed in ng mL À1 .
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (version 5.01 for Windows; GraphPad Software, San Diego, CA, U.S.A.). Semiquantitative real-time PCR and ELISA were evaluated by means of the nonparametric Mann-Whitney test. Spearman's rank correlation coefficient (r S ) was used for statistical analysis of correlations. P-values < 0Á05 were considered statistically significant.
Results
Interleukin-32 protein is expressed in lesional hidradenitis suppurativa skin
Immunohistochemical analysis of IL-32 protein expression was performed on tissue sections of lesional HS biopsies. As controls, lesional skin from healthy skin and patients with AD or psoriasis was analysed. Representative examples of IL-32 staining are shown in Figure 1 . Whereas lesional HS skin showed scattered IL-32 + cells in highly inflamed regions of the deep dermis without any accumulation around the hair follicle, IL-32 + cells were almost absent from healthy skin and lesional AD and psoriatic skin.
Expression of interleukin-32 in lesional hidradenitis suppurativa skin by T cells, macrophages, natural killer cells and dendritic cells
It has previously been shown that IL-32 is expressed by T cells, macrophages, natural killer cells and dendritic cells. 5 We therefore performed a double immunofluorescence analysis to determine whether these cell types are producing IL-32 in lesional HS skin. We detected colocalization of IL-32 with CD3, CD68, CD56 and CD11c (Fig. 2) . Hence our data suggest that IL-32 is produced by T cells, macrophages, natural killer cells and dendritic cells in lesional HS skin.
IL32 mRNA is upregulated in lesional hidradenitis suppurativa skin
After determining that IL-32 protein expression was increased in lesional HS skin, we sought to investigate whether this is also true on the mRNA level, and which IL-32 isoforms are contributing to this increase. Therefore, we used semiquantitative real-time PCR to determine total IL32 expression, as well as expression of the main isoforms IL-32a, IL-32b, IL-32c and IL-32d in lesional HS, AD and psoriatic skin, and healthy skin. Relative changes in gene expression between healthy and patient skin are shown in Figure 3 . In accordance with our immunohistochemical results, overall IL32 expression was specifically elevated in HS skin. While IL-32a and IL-32b were significantly increased in HS compared with healthy skin, IL32d was only slightly elevated. In HS, IL-32c was not found to be differently regulated compared with healthy skin, but Results of analyses of IL32 mRNA expression in HS compared with psoriasis (PS), atopic dermatitis (AD) and healthy skin. Threshold cycle values were normalized with the housekeeping genes HPRT1, GAPDH and B2M to healthy skin (set as a value of 1). HS, n = 20; PS, n = 8, AD, n = 8; healthy skin, n = 10. Data are presented as the mean with SEM and were statistically analysed with the Mann-Whitney test. *P < 0Á05, **P < 0Á01, ***P < 0Á001.
interestingly a significant downregulation of IL-32c was found in both lesional psoriatic and AD skin compared with healthy skin.
Positive correlation of IL32 mRNA expression with lesional inflammatory status, IFN-c and IL-17 in lesional hidradenitis suppurativa skin
Next, we assessed the potential pathogenic role of IL-32 in HS by investigating the correlation of IL-32 both with lesional parameters of disease severity and with the main cytokines produced by Th1, Th2 and Th17 cells (IFN-c, IL-13 and IL-17, respectively). Our data demonstrate that IL32 mRNA expression levels in HS positively correlate with the lesional inflammatory status (mean number of T cells, macrophages and neutrophils, see Materials and methods) (Fig. 4a) . In particular, IL-32 levels correlated with the amount of T cells (Fig. 4b) and macrophages (Fig. 4c) . Interestingly, IFN-c and IL-17, the cytokines that characterize the Th1 and Th17 lineage, positively correlated with IL-32 levels (Fig. 4d, e) , whereas the level of IL-13, which is a Th2 signature cytokine, decreased with increasing amounts of IL-32 in lesional HS skin (Fig. 4f) .
Systemic interleukin-32 levels are elevated in patients with hidradenitis suppurativa
To investigate whether systemic levels of IL-32 are also elevated in patients with HS, as observed in lesional HS skin samples, we determined IL-32 levels in serum samples from patients with HS, AD and psoriasis and from healthy donors (Fig. 5) . Serum levels of IL-32 were only significantly elevated in patients with HS when compared with healthy donors.
Discussion
Here we show that IL-32 is upregulated in skin lesions and in the serum of patients with the recalcitrant skin disease HS. Levels of IL32 mRNA in lesional HS skin positively correlate with the presence of T cells and macrophages, as well as with Threshold cycle values were normalized with the housekeeping genes HPRT1, GAPDH and B2M to healthy skin (set as a value of 1); n = 20. Significance of correlation was determined with the Spearman's rank correlation coefficient. *P < 0Á05, **P < 0Á01.
IFN-c and IL-17 levels, suggesting that IL-32 is induced as a secondary event in HS immunopathogenesis. In our hands, IL-32 is specifically upregulated in HS, but not in AD or psoriasis. Even though there might be a trend towards elevated expression in AD, as proposed by Meyer et al., 31 no significant differences between patients with AD and healthy controls could be detected in this study. Interestingly, we report no downregulation of the IL-32c isoform in lesional HS skin compared with healthy skin, as was seen in lesional psoriatic and AD skin. As previously demonstrated, IL-32c can be spliced into IL-32b as a measure to control its proinflammatory potential, 32 which suggests that this attenuation is reduced in HS compared with lesional psoriatic or AD skin. The functional relevance of IL-32 in HS lesions remains unclear and requires further investigation. We hypothesize that IL-32, with its strong proinflammatory potential, is important in leading to and maintaining a state of chronic inflammation in lesional HS skin. Our arguments in favour of this hypothesis are that, firstly, previous studies showed that IL-32 drives Th1/Th17 polarization both in vitro and in vivo. 33 Our data reveal a positive correlation between lesional IL32 mRNA levels and IFN-c and IL-17, and a negative correlation between IL-32 and IL-13, indicating that this T-cell-polarizing effect is also present in lesional HS skin. Additionally, IL-32 could be an important player in the appearance of AMPs, inducing IFN-c/IL-17 double-positive cells in HS. 20, 34 Secondly, IL-32 could upregulate other proinflammatory cytokines in lesional HS skin, similarly to rheumatoid arthritis, where IL-32 exacerbates joint inflammation by upregulating IL-1b, IL-6, IL-8 and CCL20. 35 Thirdly, IL-32 could potentially induce proinflammatory signalling pathways (nuclear factor-jB, p38 mitogen-activated protein kinase). 6 Lastly, IL-32 could maintain inflammation in lesional HS skin by maturing and redifferentiating the local innate immune system; for example, IL-32 is able to differentiate primary human monocytes into potent dendritic cells 36 and can redifferentiate dendritic cells into actively phagocytosing macrophage-like cells. 37 The most unexpected finding is that IL-32 is upregulated only in HS and not in AD or psoriasis. Previous studies in psoriasis show contrasting results. While a large case study found no upregulation of IL-32 in psoriasis, 38 another study found IL-32 to be elevated in lesional psoriatic skin. 39 51 This, taken together with the fact that IL-32 can be produced by adipocytes and that obese people have higher serum levels of IL-32, 52 could explain why HS and obesity are so tightly related. Treating HS by influencing the immune system is promising, but trials to block IL-1b in patients with HS have yielded conflicting results. [53] [54] [55] As IL-32 can induce IL-1b, blocking IL-32 would reduce IL-1b induction and could therefore be a promising target to abrogate the proinflammatory cascade. This is supported by the study of Joosten et al., 56 where it was reported that in mice, injection of IL-32 alone is able to induce joint inflammation in an even more pronounced manner than IL-1b or TNF-a.
Taking the evidence together, we report here that IL-32 is upregulated in patients with HS, but not in patients with psoriasis or AD. We were able to correlate inflammatory status and Th1 and Th17 cytokines with IL32 mRNA levels in lesional HS skin and were able to show that IL-32 is produced by T cells, macrophages, natural killer cells and dendritic cells in HS. Further investigation of the involvement of the IL-32 pathway will help us to understand the pathological mechanisms in HS and could pave the way for future treatment possibilities by blocking IL-32 in this recalcitrant skin disease.
